Introduction
Methods
Results
Patients
Parameters | No. of patients | Percent (%) |
---|---|---|
Sex | ||
Male | 24 | 44.4 |
Female | 30 | 55.6 |
Age at onset | ||
Mean | 52.5 | |
Median | 54.0 | |
Range | 24–76 | |
Age at the beginning of STZ administration | ||
Mean | 56.0 | |
Median | 56.0 | |
Range | 31–77 | |
Performance status | ||
0 | 34 | 63.0 |
1 | 17 | 31.5 |
2 | 3 | 5.5 |
3–4 | 0 | 0.0 |
Primary site | ||
Pancreaticoduodenal NET | (46) | (85.2) |
Pancreas head | 12 | 26.1 |
Pancreas body | 10 | 21.7 |
Pancreas tail | 19 | 41.3 |
Head, body and tail | 1 | 2.2 |
Duodenal | 4 | 8.7 |
Gastrointestinal NET | (8) | (14.8) |
Stomach | 2 | 25.0 |
Small Intestine | 1 | 12.5 |
Rectum | 4 | 50.0 |
Others | 1 | 12.5 |
Pathological diagnosis (WHO 2000) | ||
Well-differentiated endocrine tumor | 0 | 0.0 |
Well-differentiated endocrine carcinoma | 52 | 96.4 |
Poorly-differentiated endocrine carcinoma/small cell carcinoma | 1 | 1.8 |
Others | 1 | 1.8 |
Functioning NET/non-functioning NET | ||
Functioning | (18) | (33.3) |
Gastrinoma | 9 | 16.7 |
Insulinoma | 7 | 13.0 |
Glucagonoma | 4 | 7.4 |
Somatostatinoma | 1 | 1.9 |
Serotonin, tachykinins producing tumor | 1 | 1.9 |
Non-functioning | (36) | (66.7) |
Metastatic site(s) | ||
Liver | 53 | 98.1 |
Lymph nodes | 26 | 48.1 |
Peritoneum | 3 | 5.6 |
Lung | 2 | 3.7 |
Others | 10 | 18.5 |
Tumor characteristics
STZ therapy
Parameters | No. of patients | Percent (%) |
---|---|---|
Dosing route | ||
Intravenous (IV) | 35 | 64.8 |
Intra-arterial (IA) | 3 | 5.6 |
IV/IA | 15 | 27.8 |
Unknown | 1 | 1.9 |
Dosing regimen | ||
Daily | 14 | 25.9 |
Weekly/bi-weekly | 31 | 57.4 |
Daily/weekly | 3 | 5.6 |
Others | 6 | 11.1 |
Antitumor agents combined with STZ | ||
Doxorubicin | 1 | 1.9 |
Fluorouracil (5-FU) | 15 | 27.8 |
Oral fluoropyrimidine (S-1) | 6 | 11.1 |
Tegafur-uracil (UFT) | 26 | 48.1 |
Octreotide | 20 | 37.0 |
Mitomycin C | 3 | 5.6 |
Interferon | 1 | 1.9 |
Sunitinib | 1 | 1.9 |
None (STZ monotherapy) | 13 | 24.1 |
Tumor response according to RECIST criteria | All cases | Pancreaticoduodenal NET | Gastrointestinal NET | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Subtotal | STZ monotherapy | Combination therapy | Subtotal | STZ monotherapy | Combination therapy | |||||||||
n
| % |
n
| % |
n
| % |
n
| % |
n
| % |
n
| % |
n
| % | |
54 | 46 | 14 | 32 | 8 | 4 | 4 | ||||||||
CR | 2 | 4.3 | 2 | 5.3 | 1 | 11.1 | 1 | 3.4 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
PR | 11 | 23.9 | 9 | 23.7 | 3 | 33.3 | 6 | 20.7 | 2 | 25.0 | 1 | 25.0 | 1 | 25.0 |
SD | 9 | 19.6 | 8 | 21.1 | 1 | 11.1 | 7 | 24.1 | 1 | 12.5 | 0 | 0.0 | 1 | 25.0 |
PD | 25 | 54.3 | 20 | 52.6 | 5 | 55.6 | 15 | 51.7 | 5 | 62.5 | 3 | 75.0 | 2 | 50.0 |
UK | 7 | 7 | 4 | 3 | 0 | 0 | 0 |
Adverse events |
n
| % | CTCAE grade | ||||
---|---|---|---|---|---|---|---|
G1 | G2 | G3 | G4 | Unknown | |||
Gastointestinal disorder | |||||||
Abdominal pain | 1 | 1.9 | – | 1 | – | – | – |
Diarrhea | 2 | 3.7 | 1 | 1 | – | – | – |
Epigastric pain | 1 | 1.9 | 1 | – | – | – | – |
Nausea | 12 | 22.2 | 5 | 4 | 3 | – | – |
Acute pancreatitis | 1 | 2.9 | – | 1 | – | – | – |
Vomiting | 7 | 13.0 | 1 | 3 | 3 | – | – |
Hematolymphoid system disorder | |||||||
Leukopenia | 1 | 1.9 | 1 | – | – | – | – |
Neutropenia | 2 | 3.7 | 1 | 1 | – | – | – |
Thrombocytopenia | 1 | 1.9 | 1 | – | – | – | – |
Ocular lesion | |||||||
Abnormal ocular sensation | 1 | 1.9 | – | – | – | – | 1 |
Hepatobiliary system disorder | |||||||
Liver function abnormality | 1 | 1.9 | 1 | – | – | – | – |
Nerve system disorder | |||||||
Syncope | 1 | 1.9 | – | – | 1 | – | – |
Headache | 1 | 1.9 | – | – | – | – | 1 |
Others | |||||||
Lethargy | 4 | 7.4 | 3 | 1 | – | – | – |
Back pain | 1 | 1.9 | – | 1 | – | – | – |